| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
| 06 Nov 2026 | 10-Q |
| 06 Nov 2026 |
8-K: Results of Operations and Financial Condition
DALLAS, Texas, November 6, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the third quarter ended September 30, 2026, and provided business updates. |
| 19 Oct 2026 |
Form 4: Kalofonos Isabel, Chief Commercial Officer
Granted 92,000 Employee Stock Option (right to buy) |
| 19 Oct 2026 |
Form 4: Post Leonard E, Director
Received 1,000 shares by exercise or conversion ($600) · Sold 1,000 shares ($62.1K) |
| 19 Oct 2026 |
Form 3: Kalofonos Isabel, Chief Commercial Officer
No securities owned |
| 15 Oct 2026 | 144 |
| 21 Sep 2026 | 144 |
| 17 Sep 2026 | 144 |
| 17 Sep 2026 |
Form 4: Post Leonard E, Director
Received 1,000 shares by exercise or conversion ($600) · Sold 1,000 shares ($73K) |
| 11 Sep 2026 | 144 |
| 02 Sep 2026 | 144 |
| 31 Aug 2026 | 144 |
| 27 Aug 2026 | 144 |
| 25 Aug 2026 | 144 |
| 24 Aug 2026 | 144 |
| 19 Aug 2026 | 144 |
| 18 Aug 2026 |
Form 4: Post Leonard E, Director
Received 1,000 shares by exercise or conversion ($600) · Sold 1,000 shares ($74.5K) |
| 17 Aug 2026 | 144 |
| 14 Aug 2026 | 144 |
Loading...